E. coli Infection in Dogs (Colibacillosis)

Research is shifting from pure pathogen detection toward integrated risk profiles from bacterial genetics, microbiome, and host factors. At the center is the distinction between harmless intestinal inhabitants and pathogenic E. coli lineages: virulence and resistance genes (e.g., adhesins, toxins, efflux pumps) are evaluated together in panels and linked to clinical outcome data. Metagenomics and metabolomics examine how dysbiosis, dietary fiber content, and bile acids promote the “switching” into an inflammatory environment. In parallel, the role of biofilms in the intestinal mucosa is analyzed—critical for relapses and treatment failure.

Diagnostically, quantitative thresholds and multi-target PCRs are being developed that map toxin and adhesion profiles along with resistance markers, thus distinguishing between colonization and disease relevance. Therapeutically, the focus is shifting to targeted, short-duration antibiotic administration and microbiome-steering measures: highly digestible diets with defined fiber matrix, pre-/probiotic consortia, and postbiotics. Pilot approaches are testing bacteriophages and specific anti-adhesion molecules to decouple pathogens without damaging the entire microbiome.

Another focus is the One Health perspective: the exchange of E. coli lineages between dog, human, and environment, as well as the role of feed chains and hygiene factors. Future algorithms will integrate genotype, microbiome signature, clinical presentation, and course to predict relapse risk and select the most rapidly effective therapy—with less resistance pressure, more stable intestinal barrier, and faster convalescence.